Mirati Therapeutics, Inc. (NASDAQ:MRTX) had its price objective raised by Leerink Swann from $7.00 to $9.00 in a research report released on Friday morning. The firm currently has a market perform rating on the biotechnology company’s stock.

Other equities research analysts have also issued research reports about the stock. Jefferies Group LLC set a $5.00 price target on shares of Mirati Therapeutics and gave the company a hold rating in a report on Friday, August 4th. ValuEngine lowered shares of Mirati Therapeutics from a sell rating to a strong sell rating in a report on Thursday, September 7th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. Mirati Therapeutics has an average rating of Hold and a consensus target price of $8.15.

Shares of Mirati Therapeutics (NASDAQ:MRTX) traded up 135.79% during midday trading on Friday, reaching $11.20. 48,767,398 shares of the company’s stock were exchanged. The company’s market cap is $279.65 million. The stock’s 50 day moving average price is $5.21 and its 200 day moving average price is $4.48. Mirati Therapeutics has a 12-month low of $2.70 and a 12-month high of $12.40.

COPYRIGHT VIOLATION NOTICE: “Mirati Therapeutics, Inc. (MRTX) Price Target Increased to $9.00 by Analysts at Leerink Swann” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/16/mirati-therapeutics-inc-mrtx-price-target-increased-to-9-00-by-analysts-at-leerink-swann.html.

Several institutional investors have recently modified their holdings of the company. Broadfin Capital LLC grew its position in shares of Mirati Therapeutics by 19.1% in the 2nd quarter. Broadfin Capital LLC now owns 2,490,801 shares of the biotechnology company’s stock worth $9,091,000 after buying an additional 400,000 shares during the last quarter. Susquehanna International Group LLP grew its position in shares of Mirati Therapeutics by 46.5% in the 2nd quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock worth $184,000 after buying an additional 16,030 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Mirati Therapeutics by 845.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 98,251 shares of the biotechnology company’s stock worth $359,000 after buying an additional 87,858 shares during the last quarter. PDT Partners LLC purchased a new position in shares of Mirati Therapeutics in the 2nd quarter worth approximately $200,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Mirati Therapeutics by 53.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 199,563 shares of the biotechnology company’s stock worth $728,000 after buying an additional 69,377 shares during the last quarter. 60.17% of the stock is currently owned by hedge funds and other institutional investors.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Stock Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related stocks with our FREE daily email newsletter.